Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn’s disease

Table 4 Antiphospholipid antibodies and clinical characteristics of complication and surgery naïve Crohn’s disease patient cohort n (%)

Factor	Follow-up of CD B1 at first sampling total cohort (n = 143)
	CD B1 total	No complication	Perianal change only (B1p)	Behaviour change to B2 or B3	No surgery	Surgery
	(n = 143)	(n = 114)	(n = 7)	(n = 22)	(n = 130)	(n = 13)
Male/female (n)	60/83	45/69	5/2	10/12	55/75	5/8
Age at presentation (yr)1	25 (19.0-34.0)	26 (20.0-34.3)	17 (14.0-31.0)	25 (18.8-34.8)	25 (19.0-34.0)	31 (18.0-35.5)
Duration (yr)1	3 (1.0-6.0)	2 (1.0-7.0)	3 (1.0-5.0)	3 (1.0-5.0)	2 (1.0-6.0)	3 (1.0-10.0)
Location
L1	30 (21.0)	24 (21.1)	0 (0.0)	6 (27.3)	26 (20.0)	4 (30.8)
L2	51 (35.7)	44 (38.6)	3 (42.9)	4 (18.2)	48 (36.9)	3 (23.1)
L3	62 (43.3)	46 (40.4)	4 (57.1)	12 (54.5)	56 (43.1)	6 (46.2)
L4 only	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Frequent relapse	27 (18.9)	18 (15.8)2	4 (57.1)2	5 (22.7)	23 (17.7)	4 (30.8)
Smoking habit yes	21 (16.2)	14 (12.3)2	2 (28.6)	8 (36.4)2	21 (16.2)	3 (23.1)
Follow up time from first sampling, mo1	53.4 (38.0-79.3)	51.7 (36.9-73.9)	79.8 (42.9-91.4)	64.7 (45.6-85.0)	50.93 (37.25-74.2)	84.03 (60.0-91.7)
Positive markers
Anti-β2-GPI IgG	1.4	1.8	0	0	1.6	0
Anti-β2-GPI IgM	5.0	5.3	16.7	0	5.5	0
Anti-β2-GPI IgA	2.8	1.8	16.7	4.5	3.1	0
Any anti-β2-GPI	8.5	8.8	16.7	4.5	9.4	0
ACA IgG	9.2	11.5	0	0	10.2	0
ACA IgM	2.8	3.5	0	0	3.1	0
ACA IgA	17.0	18.6	33.3	4.5	18.8	0
Any ACA	19.9	22.1	33.3	4.5	21.9	0
Anti-PS/PT IgG	8.5	8.0	0	13.6	7.8	15.4
Anti-PS/PT IgM	7.8	8.8	16.7	0	7.8	7.7
Anti-PS/PT IgA	9.9	9.7	16.7	9.1	10.9	0
Any anti-PS/PT	20.6	19.5	33.3	22.7	20.3	23.1

¹Median (IQR);

²Using χ²-test with Yates correction (P≤ 0.01);

³Using Mann-Whitney test (P < 0.01). Location: L1: Ileal; L2: Colonic; L3: Ileocolonic; L4: Upper gastrointestinal disease; Behavior: B1: Inflammatory; B2: Stenosing; B3: Penetrating. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex; CD: Crohn’s disease.